One possible mechanism is that CMTM6 binds with PD-L1 protein, decreases its ubiquitination and increases the half-life of PD-L1 protein, resulting in enhanced ability of tumor cells to inhibit T cells; the elimination of CMTM6 would reduce PD-L1 and improve OS. The gene discussed is CD274; the disease is neoplasm.